Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : CVTX - CV Therapeutics, Inc. -- Ignore unavailable to you. Want to Upgrade?

To: rkrw who wrote (118)	11/11/2003 11:45:23 AM
From: scaram(o)uche	Read Replies (1) \| Respond to of 411

>> From CV's S1 9/25/1996!! << going out on a limb here...... if I remember correctly....... the first molecule with designation of "adentri" failed in clinical trials. however, proof of concept-like results were observed, and the companies decided to work up a second molecule which inherited the adentri program name?? furthermore, I believe that the top-line results were obtained from THIS molecule over a year ago, and that this release by Biogen was only a meeting rehash. All guesses, faint memories, and misc. similar strong data.